Stem Cell Therapy Market Synthesis and Opportunity Assessment 2019-2024 – Markets Gazette

Global Stem Cell Therapy Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024:This report tracks the major market events including product launches, development trends, mergers & acquisitions and the innovative business strategies opted by key market players. Along with strategically analysing the key markets, the report also focuses on industry-specific drivers, restraints, opportunities and challenges in the Stem Cell Therapy market.

In the last several years, global stem cell therapy market developed fast at a average growth rate of 46.81%. In 2017, the global stem cell therapy market size was 235 million USD, and the market is expected to be 277 million USD.

On the basis of therapeutic application, the global stem cell therapy market is segmented into Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, and other applications. The musculoskeletal disorders and Wounds & Injuries are expected to dominated the market.

According to this study, over the next five years the Stem Cell Therapy market will register a 20.7% CAGR in terms of revenue, the global market size will reach US$ 710 million by 2024, from US$ 280 million in 2019.

Top Companies in the Global Stem Cell Therapy Market: INTERSCIENCE, IUL,S.A., UVP, AID, BioMerieux, Schuett, Synbiosis, BioLogics, WTW, Bibby Scientific, SK-Electronics, SP Scienceware, KROWNUS, Instem, Rocker, Shineso, ORIENTOP, Wseen, Yalien, YLN others.

Click the link to Get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/03051125289/global-stem-cell-therapy-market-growth-status-and-outlook-2019-2024/inquiry?source=nevadagreentimes&Mode=54

This report segments the global Stem Cell Therapy market on the basis of Type are:

On the basis of Application, the Global Stem Cell Therapy market is segmented into:

For comprehensive understanding of market dynamics, the global Stem Cell Therapy market is analyzed across key geographies namely:

North America (United States, Canada, Mexico)

Asia-Pacific (China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam)

Europe (Germany, France, UK, Italy, Russia, Rest of Europe)

Central & South America (Brazil, Rest of South America)

Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Other)

Avail Discount at (Special Offer: This report is available up to 10% discount for a limited time only):

https://www.marketinsightsreports.com/reports/03051125289/global-stem-cell-therapy-market-growth-status-and-outlook-2019-2024/discount?source=nevadagreentimes&mode=54

-Comprehensive assessment of all opportunities and risk in the Stem Cell Therapy market.

-Stem Cell Therapy market recent innovations and major events.

-Detailed study of business strategies for growth of the Stem Cell Therapy market-leading players.

-Conclusive study about the growth plot of Stem Cell Therapy market for forthcoming years.

-In-depth understanding of Stem Cell Therapy market-particular drivers, constraints and major micro markets.

-Favourable impression inside vital technological and market latest trends striking the Stem Cell Therapy market.

Buy Full Report

https://www.marketinsightsreports.com/report/purchase/03051125289?mode=su?source=nevadagreentimes&Mode=54

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

-Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

-Analytical Tools: The Global Stem Cell Therapy Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Finally, Stem Cell Therapy Market report is the believable source for gaining the Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and Market development rate and figure and so on. This report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com | irfan@marketinsightsreports.com

The rest is here:
Stem Cell Therapy Market Synthesis and Opportunity Assessment 2019-2024 - Markets Gazette

R3 Stem Cell Launches Master Class Series on Stem Cell Therapy and Regenerative Medicine – PRNewswire

PHOENIX, Oct. 1, 2019 /PRNewswire/ --R3 Stem Cell, a national leader in stem cell therapy marketing and education, today announced that they are launching a new Master Class centered around the topic of stem cells and regenerative procedures. To commemorate their launch, they will be giving away one out of the eight episodes of their Master Class series for free and the rest will be available for only $49. Purchase the R3 Stem Cell Master Class series and receive Stem Cell Therapy with an R3 Center for $500 off. Register for the Master Class at https://stemcellmasterclass.org/.

The Master Class offers those considering regenerative procedures with stem cells vital information such as discovering how the process works, understanding the options that are given to them, learning the research behind it and gaining realistic expectations.

"Experiencing chronic pain is tiring and can lead to anxiety, depression, obesity, and addiction of medication," said David Greene, MD, MBA, Founder and CEO of R3 Stem Cell. "For those who are considering a stem cell procedure, our Master Class will provide them with the knowledge needed in order to make the decision. Questions regarding common misconceptions in the ever-growing field will be uncovered, giving the patient a realistic understanding of what a stem cell is, where they come from and what they can do."

The Master Class series explains what to expect with a regenerative procedure investment, what the different ways are to optimize stem cell therapy outcomes, what to look for in a stem cell clinic, and a patient's real-life experience with a stem cell procedure. The series is divided into eight different episodes, offering the patient a four-hour long learning opportunity with information on discovering a procedure that is right for them.

"It is important for patients to fully understand what type of stem cell therapies are being offered to them and know the full effect it can have on their everyday lives," continues Dr. Greene. "Regenerative therapies may give patients the opportunity to return to pain-free personal everyday activities. Our purpose is to make people educated consumers in a time when so much misinformation is being disseminated."

About R3 Stem Cell

R3 Stem Cell offers regenerative stem cell therapies to those who suffer from chronic pain. Their sole purpose is to repair, regenerate, and restore damaged tissue from the body. Giving hope and options for patients of relieving chronic pain and avoiding surgery. Stem cell procedures are done using bone marrow, adipose, amniotic, PRP or umbilical cord tissue containing platelets, cytokines, growth factors and exosomes that work to start a healing process within the body and repair damaged tissue. R3 Stem Cell has over 35 nationwide Centers and there is most likely a clinic near you. To learn more about R3 Stem Cell, visit their website at http://www.r3stemcell.comor call (844) GET-STEM.

Media Contact

Jennifer RodriguezFirecracker PR(888)317-4687 ext. 703223962@email4pr.com

SOURCE R3 Stem Cell

Homepage 2018

Go here to read the rest:
R3 Stem Cell Launches Master Class Series on Stem Cell Therapy and Regenerative Medicine - PRNewswire

ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research Center -…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ElevateBio, a Cambridge-based biotechnology holding company, today announced it has established and launched HighPassBio, a company dedicated to advancing novel targeted T cell immunotherapies. The companys lead product is an engineered T cell receptor (TCR) T cell therapy for HA-1 expressing tumors, which is designed to treat and potentially prevent relapse of leukemia following hematopoietic stem cell transplant (HSCT). The product and approach were developed by researchers at Fred Hutchinson Cancer Research Center.

At ElevateBio we are committed to building therapeutics companies with the worlds leading innovators in cell and gene therapy to advance novel treatments that have strong potential to dramatically improve patient lives, said David Hallal, Chairman and CEO of ElevateBio. We look forward to leveraging our centralized industry-leading cell and gene therapy process development and manufacturing capabilities while working closely with Dr. Marie Bleakley and her team, to accelerate their impressive work through clinical development with the goal of serving patients who have no other treatment options. Additionally, we will explore this approach as a potential treatment for other diseases that are treated by stem cell transplants.

HighPassBios scientific founder is Marie Bleakley, M.D., Ph.D., M.ClinEpi, pediatric oncologist and stem cell transplant physician at Fred Hutchinson Cancer Research Center and chair of the scientific advisory board (SAB) of HighPassBio. As the chair of HighPassBios SAB, Dr. Bleakley will continue working with ElevateBio to advance and accelerate this innovative program through clinical development toward patients.

A Phase 1 clinical trial has treated initial patients and is recruiting adult and pediatric patients who have relapsed with leukemia or related conditions following blood and marrow transplantation (also known as stem cell transplantation). More details on http://www.clinicaltrials.gov under the study ID number NCT03326921.

About TCR-Engineered T Cell Therapy

A key role of the immune system is to detect tumor antigens, engage T cells and eradicate the tumor. However, the immune response to tumor antigens varies and is often insufficient to prevent tumor growth and relapse. An approach known as adoptive T cell therapy, using T cell receptors, or TCRs, can overcome some of the obstacles to establishing an effective immune response to fight off the target tumor. TCRs are molecules found on surface of T cells that can recognize tumor antigens that are degraded to small protein fragments inside tumor cells. Unlike CAR T cells that recognize only surface antigens, TCRs can recognize small protein fragments derived from intracellular and surface antigens offering a more diverse way to attack tumors. These small protein fragments show up on the tumor cell surface with another protein called major histocompatibility complex (MHC), get recognized by the TCRs and consequently signal the bodys immune system to respond to fight off and kill the tumor cells.

Tumor-specific TCRs can be identified and then engineered into T cells that recognize and attack various types of cancers, representing a novel approach to treating and potentially preventing disease.

Adoptive T cell therapy can be applied to tackling relapse of leukemia post hematopoietic stem cell transplant (HSCT) by targeting the antigens expressed only by the patient and not by the stem cell transplant donor, known as minor histocompatibility antigens, or HA1. HA1 is expressed predominantly or exclusively on hematopoietic cells and leukemic cells. There is evidence that T cells specific for HA1 can induce a potent and selective antileukemic effect. HA1 TCR T cell therapy is a new investigational immunotherapy for the management of post transplantation leukemia relapse.

About Leukemia post HSCT Treatment and the Risk of Relapse

Leukemia, a cancer of the blood or bone marrow characterized by an abnormal proliferation of blood cells, is the tenth most common type of cancer in the U.S. with an estimated 60,140 new cases and 24,400 deaths in 2016. Leukemia arises from uncontrolled proliferation of a specific type of hematopoietic (blood) cell that is critical for a functional immune system. As a result, when patients are given very high doses of chemotherapy to eradicate leukemic cells most normal cells are killed as well, necessitating a transplant of hematopoietic stem cells from a donor to reconstitute the patients bone marrow and circulating hematopoietic cells. In some cases, the transplanted T cells from the donor can also recognize and eliminate the hematopoietic cells, including leukemia, from the recipient, thus preventing relapse.

While the majority of HSCT recipients are cured, 25-50 percent of HSCT recipients relapse, leukemia relapse remains the major cause of allogeneic HSCT failure, and the prognosis for patients with post-HCT relapse is poor. Relapse occurs following allogeneic HSCT in approximately one-third of patients with acute leukemia who undergo the procedure, and most patients subsequently die of their disease.

About HighPassBio

HighPassBio, an ElevateBio portfolio company, is working to advance a novel approach to treating hematological malignancies by leveraging T cell receptor (TCR)-engineered T cells, known as TCR T cells. The companys lead program is designed to treat or potentially prevent relapse of leukemia in patients who have undergone hematopoietic stem cell transplant (HSCT). The technology was born out of Fred Hutchinson Cancer Research Center by world renowned expert, Dr. Marie Bleakley.

About ElevateBio

ElevateBio, LLC, is a Cambridge-based cell and gene therapy holding company, established to create and operate a broad portfolio of cell and gene therapy companies with leading academic researchers, medical centers and entrepreneurs. ElevateBio builds single- and multi-product companies by providing scientific founders with fully integrated bench-to-bedside capabilities including world-class scientists, manufacturing facilities, drug developers and commercial expertise. ElevateBio BaseCamp, a company-owned Cell and Gene Therapy Center of Innovation, will serve as the R&D, process development and manufacturing hub across the entire ElevateBio portfolio while also supporting selected strategic partners.

ElevateBios lead investors are the UBS Oncology Impact Fund (OIF) managed by MPM Capital, as well as F2 Ventures. Investors also include EcoR1 Capital, Redmile Group, and Samsara BioCapital.

Excerpt from:
ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research Center -...

Regenerative Stem Cell Therapy Pioneer, Celavie Biosciences, LLC, to Attend Cell & Gene Meeting on the Mesa on October 2 4 in Carlsbad,…

OXNARD, Calif.--(BUSINESS WIRE)--Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, announced today their attendance at the Alliance of Regenerative Medicines (ARM) Cell & Gene Meeting on the Mesa to be held October 2nd 4th in Carlsbad, California.

Sandy Solmon, CEO and President, and Oleg Kopyov, MD, PhD, Executive Vice President and Chief Scientific Officer, will attend the conference and take meetings to explore collaboration and funding opportunities for further development of Celavies human and veterinary clinical programs.

At partnering meetings, Celavie will discuss their lead clinical program for the application of the companys human undifferentiated allogeneic pluripotent stem cells in Parkinsons disease (PD). Celavie recently published exploratory clinical data in 7 PD patients with four-year follow-up in Cell Transplantation. Celavie anticipates filing an IND with the FDA for a Phase I clinical trial in patients with moderate to advanced PD.

Celavie will also discuss their pre-clinical program in cerebellar ataxia and plans for taking their programs into further clinical development. Additionally, Celavie is actively seeking opportunities to out-license subsidiary Celavets veterinary applications in equine tendonitis and other indications.

To schedule a meeting with Celavie Biosciences at the Cell & Gene Meeting on the Mesa, please contact Sandy Solmon or Dr. Oleg Kopyov via the Cell & Gene Meeting on the Mesa partnering portal: https://www.meetingonthemesa.com/partnering/.

About the Cell & Gene Meeting on the Mesa

The Cell & Gene Meeting on the Mesa is the sector's foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 70+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,150 attendees over 20% of which are C-level executives this conference enables key partnerships through more than 2,200 one-on-one meetings while highlighting the significant clinical and commercial progress in the field. For more information, visit the website: https://www.meetingonthemesa.com/.

About Celavie Biosciences

Celavie Biosciences is a privately-held company whose mission is to improve lives and restore hope by advancing regenerative stem cell therapies for the treatment of Parkinsons disease and other disorders of the central nervous system (CNS). The company develops undifferentiated, unmodified allogeneic pluripotent stem cell-based therapies, holds a strong IP portfolio, including 18 issued patents, and has an experienced management team blending expertise in concept and cell technology, product scalability and entrepreneurship. Celavet, a subsidiary, applies the same proprietary technologies for the treatment and prevention of serious veterinary diseases. More information is available at https://www.celavie.com/.

See more here:
Regenerative Stem Cell Therapy Pioneer, Celavie Biosciences, LLC, to Attend Cell & Gene Meeting on the Mesa on October 2 4 in Carlsbad,...

Michael Schumachers surgeon denies hes performing experiments on F1 legend with stem cell treatment and sl – The Sun

MICHAEL Schumacher's doctor has warned fans that he "does not work miracles" following stem cell therapy he performed on the F1 star.

Dr Philippe Menasch has also slammed claims he was carrying out "experiments" on the legendary racing driver when he treated him in Paris last month.

4

4

Little was known about the stem-cell operation, but seven-time world champion Schumacher is believed to have received transfusions of inflammation-reducing stem cells.

Amongst the media flurry surrounding the top-secret op, local media reported on it as "experimental."

Menasche - known as a pioneer in stem-cell research - has slammed these claims, telling Italian newspaper La Republica: "I do not perform miracles.

"My team and I are not doing an experiment, an abominable term that is not in line with a serious medical view."

Schumacher's condition is not public knowledge, but after the procedure last month, a nurse toldLe Parisien: "Yes he is in my service ... And I can assure you that he is conscious."

The French paper also said Schumacher has been treated at least twice previously at the Georges-Pompidou hospital in Paris, admitted each time under a false name and treated by a small medical team.

It was also reported that the F1 driver was accompanied by security staff.

Schumacher's health has been shrouded in secrecy ever since a near-fatal brain injury he suffered in 2013.

The seven time F1 championsuffered severe head injuries on a family skiing holiday in the French Alps and has not been seen in public since.

What is stem cell therapy and how does it work?

STEM cell therapy is one of the most promising new medical treatments.

Stem cells are the body's raw materials - the cells from which all cells in the body are generated.

In the lab, scientists can take stem cells and help them divide to create daughter cells.

These daughter cells can either become new stem cells or turn into specialised cells - blood, brain, heart muscle, bone cells for example.

Scientists and doctors across the world hope stem cells could prove the breakthrough for treating a range of conditions, from heart disease to cancer.

How does it work?

One of the key ways stem cell treatment can work is to repair or regenerate damaged and diseased tissues.

By taking the cells and creating specialised heart muscle cells for example, doctors can help repair damaged heart muscle and use them to treat heart failure.

Who can benefit?

According to the Mayo Clinic in the US, patients with a wide range of illnesses and disease could benefit from the treatment.

They include those suffering:

Stem cells can also be used to grow new tissue that can then be used for transplants and regenerative medicine.

It means in future, stem cells could be used to grow new organs rather than relying on organ donation.

He was skiing with his son Mick when he fell and cracked his head on a boulder on the Combe de Saulire above Mribel.

The devastating injury left him paralysed and unable to speak.

Schumacher spent three months in a medically-induced coma after the accident and has had years of intensive care at his house in Gland, a Swiss town on the shore of Lake Geneva.

His condition now appears to have stabilised and in January this year he was taken by helicopter to the family's holiday home in Mallorca for his 50th birthday.

In a celebratory post on Instagram, his family wrote: "Please understand if we are following Michael's wishes and keeping such a sensitive subject as health, as it has always been, in privacy."

They confirmed that Schumacher was in "the very best of hands."

The wall of secrecy is reportedly enforced by his wife, Corinna.

Forumla One's head of motorsport, Ross Brawn has spoken publicly about Corinna's decision to keep her husband's health private.

He said: "I am constantly in touch with Corinna, and I totally agree with their decision."

Latest

STAR KILLED Grammy-award winning artist Louie Rankin dies in horror car crash

SPOT THE SPOTS Can YOU spot the leopard hiding in a ditch in this amazing viral pic?

SAVAGE ATTACK Woman raped female victim with gun and poured acid on her' in row over 150

'MONSTER MUM' Mother mowed down & killed daughter & another woman during birthday party'

STABBED IN CLASS Finland 'sword rampage leaves 1 dead & 9 injured as student storms school'

KILLED IN SLEEP Girl, 14, 'killed by exploding phone' after going to bed listening to music

"Michael has always been a very private person and that's been a guiding principle in his career, his life and his family always agreed with that choice.

"It's completely understandable that Corinna has wanted to maintain the same approach, even after the tragic event, and it's a decision we must all respect.

"I'm sure the millions of people who are still Michael fans will understand it, too."

4

4

We pay for your stories! Do you have a story for The Sun Online news team? Email us attips@the-sun.co.uk or call 0207 782 4368 . You can WhatsApp us on 07810 791 502. We pay for videos too. Click here to upload yours.

See the original post here:
Michael Schumachers surgeon denies hes performing experiments on F1 legend with stem cell treatment and sl - The Sun

Positive Study Results of Phase IIa Clinical Trial Using Intravenous Administration of Mesenchymal Stem Cells for Ischemic Stroke Published in…

SAN DIEGO, Sept. 30, 2019 /PRNewswire/ -- Results from a study sponsored by Stemedica Cell Technologies, Inc., a global biotechnology company that uses allogeneic stem cells for ischemic conditions, form the basis for a peer-reviewed paper published inStrokeentitled "Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke." Co-authors include Michael L. Levy, MD, PhD, John R. Crawford, MD, Nabil Dib, MD, Lev Verkh, PhD, Nikolai Tankovich, MD, PhD and Steven C. Cramer, MD.

As indicated in theStrokepublication, "Stroke is perennially among the leading causes of human disability and the leading neurological cause of lost disability-adjusted life years. The mean survival after stroke is 6-7 years, with more than 85% of patients living past the first-year post-stroke, many with years of enduring disability. Many restorative therapies are under study to improve outcomes after stroke." However, restorative therapies often have a short time window for improvement usually measured in days-months.

"Based on Stemedica's preclinical data that supported the safety and efficacy of its MSCs as a restorative therapy to improve outcomes after stroke, the company was granted approval by the FDA to conduct a Phase I/IIa dose escalation trial that examined the effects of a single IV infusion of Stemedica's cGMP manufactured allogeneic ischemia-tolerant MSCs," said Dr. Lev Verkh, Chief Regulatory and Clinical Development Officer of Stemedica.

Study:The target population included patients with chronic ischemic stroke and substantial functional deficits; a group for whom treatment options remained limited. The primary outcome of the study was safety, based on serial measures of behavior, CT scans, and laboratory testing. Four secondary endpoints were scored serially to derive estimates of behavioral changes relatively to the baseline over a period of 12 months: NIH Stroke Scale (NIHSS) for neurological assessment, Barthel Index (BI) for ability to perform daily tasks, Mini-Mental Status Exam (MMSE) for mental status, and Geriatric Depression Scale (GDS) for degree of depression. The study was conducted at three centers: University of California, San Diego (UCSD); Mercy Gilbert Medical Center, Gilbert, Arizona; and University of California, Irvine (UCI).

Entry criteria included ischemic stroke >6 months prior to administration, substantial functional deficits (subject confined to a wheelchair, had home-nursingcare, orneeded assistance withactivities ofdailyliving), no substantial improvement in neurologic orfunctional deficits for the2 months prior to enrollment in thestudypermedical history, and NIHSS score=6-20.

Enrollees received a single intravenous dose of allogeneic mesenchymal bone marrow cells. Phase I used a dose escalation design (3 tiers, n=5 each). Phase IIa (n=21) was an expanded safety cohort. The primary endpoint was safety over 1-year. Secondary endpoints examined behavior, with a pre-specified focus at 6-months.

Subject status at enrollment prior to treatment:At baseline, subjects (n=36) averaged 4.24.6 years post-stroke, age 61.110.8 years, NIHSS score 8 [6.5-10], and Barthel Index 6529.

Safety:Study testing disclosed no safety concerns. No subject showed a positive reaction to intradermal testing. In Phase I, each dose (0.5, 1.0, and 1.5 million cells/kg body weight) was found safe, as a result Phase IIa subjects received 1.5 million cells/kg. Two subjects were lost to follow-up, one was withdrawn, and two died (unrelated to study treatment). There were 15 serious adverse events, none possibly or probably related to study treatment. Two mild adverse events were possibly related to study treatment, a urinary tract infection and IV site irritation. Treatment was determined to be safe based on serial exams, EKGs, laboratory tests, and pan-CT scans.

Behavioral Effects:Improvements across all subjects post-transfusion and for all four secondary endpoints were achieved. Improvements in each index were: Barthel Index (6.811.4 points, p=0.002); in NIHSS (-1.251.7 points, p<0.001); Mini Mental Status Exam (1.82.8 points, p<0.001); and Geriatric Depression Scale (-1.63.8 points, p=0.015). At baseline 11.4% (4/35 subjects) had Barthel Index=95-100 (favorable outcome); at 6-months, 27.3% (9/33); by 12-months, 35.5% (11/31).

Conclusions:The current study is the largest trial of intravenous MSCs in patients with chronic stroke and the first to evaluate allogeneic MSC therapy in this population. It is also the first study to evaluate MSCs grown under hypoxic conditions favorable to cell proliferation, gene expression, cytokine production and migration. While patients with stroke in the chronic stage generally show significant functional decline, enrollees in the current study showed 12 months of continued functional improvements across all secondary endpoints.

Intravenous transfusion of allogeneic ischemia tolerant MSCs in patients with chronic stroke and substantial functional deficits was safe and suggested behavioral gains. These data support proceeding to a randomized, placebo-controlled study of this therapy in this population.

Dr. Nikolai Tankovich, President and Chief Medical Officer added, "Stemedica is encouraged by the results of the study which demonstrated safety and preliminary efficacy of its cell therapy product for the treatment of chronic ischemic stroke patients. It is a significant milestone for Stemedica to bring this new cellular medication to patients with debilitating conditions caused by a stroke. Stemedica plans to move forward to a Phase-IIb discussion with the FDA."

Michael Levy, MD, PhD, FACS, FAANS, Professor of Neurosurgery at UCSD and the Principal Investigator of this study commented: "Based on my clinical trial work in Stemedica's Ischemic Stroke trial, my experience to date with Stemedica's allogeneic ischemic tolerant mesenchymal stem cell product suggests that the product is first and foremost safe and secondarilyhas the potential to produce unparalleled medical benefits."

About Stemedica Cell Technologies, Inc.Stemedica Cell Technologies, Inc. is a global biopharmaceutical company that manufactures best-in-class allogeneic adult stem cells. The company is a government licensed manufacturer of cGMP, clinical-grade stem cells currently used in US-based clinical trials for ischemic stroke, and Alzheimer's Disease. Stemedica's cell are also used on a worldwide basis by research institutions and hospitals for pre-clinical and clinical (human) trials. Stemedica is currently developing additional clinical trials for other medical indications using adult, allogeneic stems cell under the auspices of the FDA and other international regulatory institutions. The company is headquartered in San Diego, California and can be found online atwww.stemedica.com.

Forward Looking StatementsThis press release may contain forward-looking statements. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance and you are cautioned not to place undue reliance on these forward-looking statements. These statements reflect the views of Stemedica as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

Media ContactStemedica Cell Technologies, Inc.Dave McGuiganEVP, Marketing & Business Developmentdmcguigan@stemedica.com+1 858-658-0910 x7203

SOURCE Stemedica Cell Technologies, Inc.

Read this article:
Positive Study Results of Phase IIa Clinical Trial Using Intravenous Administration of Mesenchymal Stem Cells for Ischemic Stroke Published in...

The Shocking Culture of Nurses and the Treatment of Patients with Sickle Cell – Nurse.org

By: Portia Wofford

September is National Sickle Cell Awareness Month. Sickle Cell hits close to home for me. My nephew has the trait. My goddaughter has the disease and is frequently in crisis. Several other family members and friends are also fighting this illness.

One of the most common issues they all deal with is treatment by healthcare professionals particularly nurses when they seek treatment for this disease. Its shameful, but often their symptoms often cause them to be mistaken for:

These are all terms thrown at people with Sickle Cell Disease (SCD). The treatment or mistreatment of Sickle Cell patients contradicts our title as the most trusted profession.

So, nurses, what can we do? How do we advocate, treat, and care for this population of patients?

SCD is a group of red blood cell disorders. Unlike healthy red blood cells (RBC) which are round, patients with SCD have RBC that take on a C or sickle shape. Sickle cells die early which causes a constant shortage of red blood cells.

SDC commonly affects those whose ancestors came from:

The only cure for SCD is bone marrow or stem cell transplant.

When sickle cells travel through small blood vessels, they get stuck and clog the blood flow causing excruciating pain and other serious problems including:

SCD warriors and their caregivers report being stigmatized when they seek care. With patients showing signs as early as birth, nurses attitudes can contribute to negative stigmatization and may affect patients' response to sickle cell cues, potentially causing patients not to seek care and negatively impacting patient outcomes.

Cleverly Changing founder Elle Cole's daughter has SCD. She gives a brief description of an ER visit after a physicians assistant at their primary care office suggested her daughter go to the nearest hospital via ambulance.

Elle recalls, In the ER, the nurse was upset and asked why we were there and which clinic sent us. She stated my daughter didnt need any oxygen, the hematologist was busy (but would come in about an hour), and she needed to get a mucus sample. My daughter was scared and started to cry. Then, the nurse told four nurses to join her, and they proceeded to hold my daughter down and extract the mucus from her nostrils. I was completely terrified! My husband was at work. I felt alone and scared with my daughter.

One mom, Shaynise Robinson, drives three to four hours to seek care for her daughter, because of the lack of understanding from nurses and other healthcare professionals at their local hospital.

In an article posted on Pubmed, researchers found that sickle cell patients in one hospital waited for 60% longer to get pain medication although other patients reported less severe pain. They were also triaged into a less serious category. 63% of nurses surveyed said many patients with sickle cell are addicted to opioids, according to another study. But according to Dr. Alexis Thompson, president of the American Society of Hematology, rates of addiction among SCD patients are no higher than the general populations.

Elle Cole, who has a blog that brings awareness to SCD, wants nurses to be patient. Asking questions that indicate that you are genuinely concerned about your patients wellbeing can help open communication with your patient.

Shauna Chin, RN, says, In my experience, in addition to the pain, many patients with SCD exhibit symptoms of depression. The nurse needs to distinguish between solemness due to pain and solemness due to despondence. Many symptoms of depression go undiagnosed and can be remedied by encouraging health providers to engage in dialogue with the patient. She expresses that nurses can advocate best for patients with SCD by identifying early non-verbal signs and symptoms of pain and anticipate their patient's needs.

Anaya Spearman, RN, BSN, believes more education is needed during nursing school. Noting in the last five years, few co-workers were adequately informed about the disease. SCD was just 'glanced over' and not taught about in-depth, in nursing school, she says. Spearman believes that SCD patients need to have a holistic care approach.

Shaynise Robinson encourages nurses to go through diversity training. Give patients the benefit of the doubt. Understand that they are looking for pain relief and equal treatment, she says. Proper bedside manner is a concern for her as well.

Sickle Cell Disease doesn't just affect the body, but the holistic health of those with the disease. Education and awareness are critical for nurses to provide proper care. Shaynise Robinson leaves us with this: The same compassion thats shown to cancer patients should be shown to sickle cell patients.

To learn more about sickle cell visit:

Sickle Cell Disease Association of America

American Sickle Cell Anemia Association

Sickle Cell Society

Portia Wofford is a staff development and quality improvement nurse, content strategist, healthcare writer, entrepreneur, and nano-influencer. Chosen as a brand ambassador or collaborative partner for various organizations, Wofford strives to empower nurses by offering nurses resources for developmentwhile helping healthcare organizations and entrepreneurs create engaging content. Follow her on Instagram and Twitter for her latest.

See more here:
The Shocking Culture of Nurses and the Treatment of Patients with Sickle Cell - Nurse.org

Brestoff, Theunissen recognized by NIH for innovative research – Washington University School of Medicine in St. Louis

Visit the News Hub

Honored with NIHs High-Risk, High-Reward Research Program awards

Thorold Theunissen, PhD, (left) and Jonathan Brestoff, MD, PhD, have received High-Risk, High-Reward Research awards from the National Institutes of Health (NIH), supporting their research programs.

Obesity expert Jonathan R. Brestoff, MD, PhD, and regenerative medicine specialist Thorold Theunissen, PhD, both of Washington University School of Medicine in St. Louis, have received High-Risk, High-Reward Research awards from the National Institutes of Health (NIH). The program supports scientists showing exceptional creativity and pursuing innovative research programs with the potential to have a wide impact in biomedical, behavioral and social sciences.

Brestoff, an assistant professor of pathology and immunology, received an NIH Directors Early Independence Award to study how the immune system regulates weight gain, with a goal of finding new ways to treat obesity beyond simply limiting food consumption. Early Independence Awards provide an opportunity for outstanding junior scientists with the intellect, scientific creativity, drive and maturity to flourish independently, launch independent research careers and bypass the traditional postdoctoral training period. The award provides up to $250,000 a year for five years.

Brestoff and others have shown that immune cells in fat tissue control how calories are stored. Recently, he discovered that fat cells can transfer their mitochondria tiny organelles responsible for generating energy in cells to macrophages, a kind of immune cell known to be involved in regulating obesity. With the new award, Brestoff will develop tools to disrupt mitochondria transfer in mice to determine the impact of this process on the function of immune cells and on the development of metabolic diseases such as obesity. The goal is to discover potential targets for medications to treat metabolic diseases.

I am honored and humbled to be selected for the NIH directors High-Risk, High-Reward program, Brestoff said. The Early Independence Award is allowing me to take my science in new, unanticipated directions at a critical point in my program and will enable my lab to explore highly innovative questions that keep me up at night. I am grateful and excited to have the opportunity to start my lab here at Washington University School of Medicine and join this incredible community of investigators.

Brestoff earned his bachelors degree at Skidmore College, followed by a masters in public health at University College Cork National University of Ireland. He then returned to the United States and earned his medical and doctoral degrees at Perelman School of Medicine at the University of Pennsylvania before completing a residency in clinical pathology at Barnes-Jewish Hospital. He joined the faculty of the School of Medicine this year. Brestoff is also a new medical director of clinical immunology in the Division of Laboratory and Genomic Medicine, where he helps to support clinical tests of the human immune system.

Theunissen, an assistant professor of developmental biology, has received an NIH Directors New Innovator Award. The award supports unusually innovative research from early-career investigators who are within 10 years of their final degrees or clinical residencies. The award provides $300,000 per year in direct funding for five years.

Theunissen studies the biology of pluripotent stem cells, which have the potential to heal or regenerate different types of tissues and organs that are damaged or diseased. Recently, he isolated a more primitive type of human stem cell that closely resembles the cells of the early human embryo. The award supports a project aimed at understanding the epigenome of these stem cells and their utility for modeling human diseases.

The epigenome refers to the layer of genetic instructions that govern how genes are regulated whether certain genes are turned off or on and to what degree they are activated. Theunissen and his research team are developing a road map to help understand the epigenetic changes that stem cells undergo as they divide and differentiate toward one tissue type or another.

It is an honor to receive this NIH directors award, Theunissen said. My colleagues in the lab and I look forward to continuing our research into the regulatory details of distinct stem cell states that could help us better understand healthy human development and what can go wrong to cause disease.

Theunissen earned his bachelors degree in biology in 2007 from Harvard University. He went on to earn a masters degree in developmental biology from the University of Cambridge in 2008 and a doctorate in biochemistry and stem cell biology, also from Cambridge, in 2011. He continued his training at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology, where he was a Sir Henry Wellcome postdoctoral fellow. In 2017, he joined the faculty of the Department of Developmental Biology at the School of Medicine, where he is also a researcher at the Center of Regenerative Medicine.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Read more here:
Brestoff, Theunissen recognized by NIH for innovative research - Washington University School of Medicine in St. Louis

CBMG: Initiating Coverage of Cellular Biomedicine Group; Multiple Cell-Based Therapies to Treat Cancer and Degenerative Diseases – Zacks Small Cap…

By David Bautz, PhD

NASDAQ:CBMG

READ THE FULL CBMG RESEARCH REPORT

Initiating CoverageWe are initiating coverage of Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) with a valuation of $24.00. Cellular Biomedicine Group is a biopharmaceutical company developing cell-based therapies for cancer and degenerative diseases, with a focus on the Chinese market. In addition to a full pipeline of development products comprised of CAR-T, TIL, and TCR, along with stem-cell based therapies for the treatment of osteoarthritis, Cellular Biomedicine Group signed a collaboration agreement last year with Novartis for the production of Kymriah in China. CAR-T products targeting multiple myeloma and non-Hodgkin lymphoma are currently being evaluated in clinical trials and we anticipate additional clinical trials initiating in other indications over the next six to twelve months.

Robust Pipeline with Multiple Cell-Therapy Development ProductsCellular Biomedicine Group has a robust pipeline of products derived from in-house discovery and strategic in-licensing including CAR-T, TIL, TCR, and stem cell products for which we anticipate at least six modalities being in Phase 1 clinical trials by the end of 2019.

Investigator-Initiated Trials to Speed-Up Development TimelinesCellular Biomedicine Group has begun investigator-initiated trials in China for its CAR-T products in patients with multiple myeloma and non-Hodgkin lymphoma, with additional trials starting later in 2019 and early 2020. These trials are intended to quickly evaluate safety and proof-of-concept in a cost-effective manner before moving to larger trials in China and the U.S. We anticipate initial data readouts from the ongoing trials at the end of 2019 or early 2020.

Collaboration with Novartis for Kymriah in ChinaIn 2018, Cellular Biomedicine Group signed a collaboration agreement with Novartis to manufacture and supply Kymriah in China. Included in the deal was a $40 million equity purchase from Novartis, which represents a 9% equity stake in the company. Cellular Biomedicine Group will be responsible for manufacturing the product while receiving an escalating single-digit royalty on net product sales of Kymriah in China, while Novartis will be responsible for distribution, regulatory, and commercialization efforts in China. This deal validates Cellular Biomedicine Groups cell manufacturing technology and we believe puts them at the forefront of cell therapy companies in China.

First-Mover Advantage in ChinaThe company is leveraging its expertise in the Chinese regulatory environment to establish itself as the leader in the Chinese cell therapy market. Very few other companies have the requisite expertise to handle the various compliance, quality assurance, and regulatory issues inherent in the Chinese market while simultaneously working to improve manufacturing timelines for cell therapy clinical trials and commercial launch.

Proprietary Manufacturing Processes for Cellular TherapiesThrough collaborations with GE Healthcare Life Sciences and ThermoFisher Scientific, Cellular Biomedicine Group has developed an automated, closed, integrated cell manufacturing system with complete control of the chain-of-custody. The company maintains manufacturing facilities totaling 100,000 ft2 in Shanghai and Wuxi that meet the quality management systems requirements of ISO 9001:2015, and the facilities of Shanghai and Wuxi sites meet local regulatory standards.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCHtoreceive our articles and reports emailed directly to you each morning. Please visit ourwebsitefor additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.

Excerpt from:
CBMG: Initiating Coverage of Cellular Biomedicine Group; Multiple Cell-Based Therapies to Treat Cancer and Degenerative Diseases - Zacks Small Cap...

Major Talent Acquisition Takes Montreal-Based Morphocell Technologies to the Next Level – BioSpace

Sept. 30, 2019 14:00 UTC

MONTREAL--(BUSINESS WIRE)-- Morphocell Technologies drive to create new clinical tools to treat currently untreatable liver conditions shifted into high gear this week with the impending addition of Dr. Jennifer Moody to its senior management team.

Dr. Moody is a stem cell commercialization and business operations expert with deep experience in the Canadian and global stem cell ecosystems, who most recently served as Senior Director of Research Operations at BlueRock Therapeutics in Toronto. She brings with her 23 years of experience in stem cell science, 13 of those years in industry commercializing products spanning from stem cell reagents to cell-based therapeutics.

Dr. Moody will assume the role of Morphocells Chief Operating Officer beginning October 7th, 2019.

It has been several years since I first met the Morphocell team and I have enthusiastically followed their progress, said Dr. Moody. The vision and drive of the founding team has significantly progressed and de-risked their technologies. I am excited to be joining the team and look forward to contributing to the advancement of Morphocells proprietary engineered liver tissue to create a cell therapy product to address the significant unmet medical need that currently exists for liver disease.

Morphocell is currently developing three revolutionary stem cell-derived products for use in acute, chronic and acute-on-chronic liver failure, which afflict millions worldwide:

We are incredibly fortunate to add Dr. Moody to our team as we ramp up toward first-in-human clinical trials for ReLiverELT, said Dr. Massimiliano Paganelli, pediatric transplant hepatologist at Sainte-Justine University Hospital Center in Montreal and co-founder of Morphocell. She brings a whole new level of expertise and savviness to our R&D, clinical trial and commercialization programs and will be a tremendous collaborator going forward.

About Morphocell Technologies

Morphocell is a Montreal-based start-up on a crusade to transform the treatment of liver disease. Preclinical assessments of the first effective stem cell-derived interventions for acute, chronic and acute-on-chronic liver failure are underway. http://www.morphocell.com / @MorphocellTech

View source version on businesswire.com: https://www.businesswire.com/news/home/20190930005189/en/

View original post here:
Major Talent Acquisition Takes Montreal-Based Morphocell Technologies to the Next Level - BioSpace